Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes:...

Area of Science:

• Cardiology
• Pharmacology

Background:

• Ranolazine is an antianginal agent effective for chronic angina.
• Its efficacy and safety in acute coronary syndromes (ACS) remained unstudied.
• This study investigated ranolazine in non-ST-elevation ACS patients.

Purpose of the Study:

• To determine the efficacy and safety of ranolazine in long-term treatment of non-ST-elevation ACS.
• To evaluate ranolazine's effect on major cardiovascular events and safety endpoints.

Main Methods:

• A multinational, randomized, double-blind, placebo-controlled trial (MERLIN-TIMI 36) involving 6560 patients.
• Patients received intravenous and oral extended-release ranolazine or placebo within 48 hours of ischemic symptoms.
• Follow-up was for a median of 348 days.

Main Results:

• The primary endpoint (cardiovascular death, MI, or recurrent ischemia) did not differ significantly between groups (21.8% vs 23.5%).
• Ranolazine significantly reduced recurrent ischemia (13.9% vs 16.1%, P=.03).
• No significant differences in all-cause mortality or symptomatic arrhythmias were observed; QTc prolongation occurred in 0.9% of ranolazine patients.

Conclusions:

• Ranolazine addition to standard ACS treatment did not reduce major cardiovascular events.
• Ranolazine demonstrated a favorable safety profile, not increasing death or arrhythmias.
• Findings support ranolazine's safety and efficacy as an antianginal therapy.